MDR · BPR · EPA · FDA · product claims
Put the disinfectant on the right regulatory pathway before testing begins
The formulation alone does not determine the route. The target, intended user, microbial claim and level of processing decide which regulator, evidence package and market authorization apply.
Product qualification
The intended target changes the regulator
Similar active substances can sit in different legal categories. Define the product from its intended use and claims before choosing tests, preparing labels or appointing a submission route.
Medical-device processing
Disinfect or sterilize a medical device
The product is specifically intended for a defined device or device category and supports a validated reprocessing endpoint.
- EU
- MDR Rule 16
- US
- FDA for critical or semicritical device endpoints
Environmental use
Disinfect or sanitize an inanimate surface
The claims address rooms, furnishings, equipment surfaces or other environmental applications rather than a high-level device endpoint.
- EU
- BPR product type 2 or 4
- US
- EPA antimicrobial pesticide
Human hygiene
Reduce microorganisms on hands or skin
The route follows the product's primary purpose, presentation, active ingredients and claims made to professional or public users.
- EU
- BPR product type 1 in the usual biocidal case
- US
- FDA over-the-counter drug
Borderline cases need a documented assessment. A general cleaning claim, a device-disinfection endpoint and a human-hygiene claim are not interchangeable, even when the underlying chemistry is similar.
Decision inputs
Resolve five questions before commissioning studies
These decisions control classification, claim wording, study design, exposure assessment and the authorities involved.
- 01
What is being treated?
A reusable medical device, noncritical equipment surface, room, food-contact area, hand or other skin site.
- 02
What result is claimed?
Cleaning, sanitization, disinfection, high-level disinfection or sterilization, with a defined microbial spectrum.
- 03
How is the product used?
Concentration, dilution, contact time, temperature, application method, rinsing, reuse and professional or consumer setting.
- 04
Which formulation reaches the market?
Active substances, excipients, packaging, shelf life, manufacturing controls and relevant formulation variants.
- 05
Where will it be placed?
Each jurisdiction applies its own definitions, claims framework, accepted methods and authorization route.
European Union
Separate the MDR route from the biocidal route
EU qualification starts with the specific intended purpose. The same product name cannot replace an assessment of the treatment target, endpoint and principal claimed function.
Products for medical devices
MDR Annex VIII Rule 16 generally places products specifically intended to disinfect or sterilize medical devices in class IIa.
- Class IIb for disinfecting solutions or washer-disinfectors specifically intended as the endpoint for invasive devices
- Class IIb for products specifically intended to disinfect, clean, rinse or hydrate contact lenses
- Physical-action-only cleaning products, other than those for contact lenses, are excluded from Rule 16
Biocidal products
The Biocidal Products Regulation covers products whose biocidal purpose protects people, animals, materials or articles through active substances.
- Product type 1 for human hygiene, including the usual hand-disinfectant case
- Product type 2 for surfaces and materials not intended for direct contact with food or feed
- Product type 4 for food and feed areas
Under the BPR, active substances must be approved for the relevant product type and the biocidal product normally requires authorization before market placement, subject to transitional and other specific provisions.
United States
FDA and EPA divide oversight by use and processing level
The old shortcut that every disinfectant used in healthcare is an FDA medical device is incorrect. The intended application determines whether EPA or FDA has primary oversight.
Environmental and noncritical surfaces
EPA regulates antimicrobial pesticides used on inanimate objects and surfaces. This generally includes general-purpose and hospital disinfectants, sanitizers and products for noncritical medical equipment surfaces.
Typical output · EPA registration strategy and claim-aligned efficacy package
Critical and semicritical medical devices
FDA regulates liquid chemical sterilants and high-level disinfectants intended for reusable heat-sensitive critical and semicritical medical devices. These products generally require a 510(k) before marketing.
Typical output · device identification, 510(k) strategy and reprocessing evidence
Hand sanitizers and antiseptics
FDA regulates hand sanitizers as over-the-counter drugs. The applicable requirements depend on the active ingredient, dosage form, claims, manufacturing arrangements and current OTC drug framework.
Typical output · ingredient, labeling, establishment and drug-compliance assessment
Evidence architecture
Make every study support a defined claim and use condition
Testing is most efficient when the intended use, regulatory category and label claims are frozen early enough to control the study matrix.
Product identity and formulation
Active substances, concentrations, specifications, impurities, manufacturing controls, packaging and variants.
Microbiological efficacy
Organisms, endpoints, standards, soil load, contact time, temperature, dilution and use simulation mapped to each claim.
Safety and exposure
Toxicological profile, residues, user and patient exposure, environmental considerations and protective measures.
Device and material compatibility
Functional performance, material effects, repeated processing, rinsing and compatibility with the specified device families.
Stability and packaging
Shelf life, in-use period, transport, container compatibility and maintenance of active concentration and efficacy.
Label and instructions
Preparation, application, contact time, limitations, warnings, disposal, claim wording and validated user steps.
MDRC delivery model
Move from product boundary to market-ready dossier
MDRC can take one decision point or coordinate the complete workstream with your technical, testing, quality and commercial teams.
- 01
Scope the product
Confirm formulations, targets, users, claims, use conditions, variants and target markets.
- 02
Determine the route
Document qualification, classification, competent authority and authorization pathway.
- 03
Plan the evidence
Map existing data, identify gaps and issue a claim-specific testing and documentation plan.
- 04
Build the dossier
Coordinate technical, efficacy, safety, labeling, quality and administrative content.
- 05
Manage the review
Support submissions, authority or notified-body questions and controlled evidence updates.
- 06
Control lifecycle change
Assess formulation, supplier, process, claim, packaging and market changes after authorization.
Product qualification and classification
Reasoned route memo, borderline analysis, authority mapping and early claim review.
Gap assessment and study planning
Claim matrix, standard selection, protocol review and evidence-reuse assessment.
Dossier and label preparation
Technical documentation, authorization content, instructions, labeling and review responses.
Submission and lifecycle support
Stakeholder coordination, submission management, change assessment and market maintenance.
Primary sources
Confirm the route against current authority requirements
Regulation (EU) 2017/745
MDR text, including Annex VIII Rule 16
ECHA understanding the BPR
Active-substance approval and product-authorization framework
EPA antimicrobial pesticides
US scope for disinfectants and sanitizers on inanimate surfaces
FDA liquid chemical sterilants
510(k) guidance and FDA–EPA jurisdiction boundary
FDA hand sanitizer information
Official overview of US OTC drug oversight
Frequently asked questions
Practical product distinctions
These answers show the main boundary. The final route must be confirmed against the actual formulation, claims, users, application and target market.
Is every disinfectant a medical device in the EU?
No. Products specifically intended to disinfect or sterilize medical devices fall within the MDR route. General surface disinfectants and products primarily intended for human hygiene usually follow the BPR, subject to their exact claims and presentation.
Which MDR class applies to a medical-device disinfectant?
Rule 16 generally assigns class IIa. Products for contact lenses are class IIb, and disinfecting solutions or washer-disinfectors specifically intended as the endpoint for invasive devices are also class IIb.
Are hospital surface disinfectants FDA medical devices?
Generally no. EPA regulates general-purpose and hospital disinfectants used on environmental and noncritical equipment surfaces. FDA regulates liquid chemical sterilants and high-level disinfectants for critical and semicritical reusable medical devices.
Do hand sanitizers follow the same route in the EU and US?
No. A product with a primary biocidal human-hygiene purpose is generally a BPR product type 1 product in the EU. In the United States, hand sanitizers are regulated by FDA as over-the-counter drugs.
Can the same efficacy studies support both markets?
Sometimes, but only when the formulation, organisms, endpoints, use conditions, methods and acceptance criteria align. A claim-by-claim gap assessment should be completed before new testing is commissioned.
Before the next study
Turn the intended use into a defensible regulatory plan
Send us the formulation, target, claims, use conditions, development status and intended markets. We will identify the critical route decisions and propose a focused scope of work.
Map your disinfectant project